BENJAMIN TRUJILLO-HERNANDEZ

Dr. BENJAMIN TRUJILLO-HERNANDEZ

Facultad de Medicina, Universidad de Colima, Colima, Mexico
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Lupus
Verified
Journal Article
Closed access
LGL Gonzalez-Lopez
L Gonzalez-Lopez
EMErnesto German GERMAN Cardona Muñoz
Ernesto German GERMAN Cardona Muñoz
ACA Celis
A Celis
ITI García-De la Torre
I García-De la Torre
GOG Orozco-Barocio
G Orozco-Barocio
JGJ I Gamez-Nava
J I Gamez-Nava
The aim of this study was to compare the efficacy of intravenouscyclophosphamide(IVCYC) versus oral enalapril in mild or moderate pulmonary hypertension (PH) in systemic lupus erythematosus (SLE). Thirty-four patients with SLE who had systolic pulmonary artery pressure (SPAP) > 30mmHg by Doppler echocardiography were randomized to receive IVCYC (0.5g/mt2 body surface area, monthly), or oral enalapril (10mg/day) for six months. The primary outcome was the significant decrease in SPAP. An additional outcome measure included the improvement in the heart functional class (NYHA). Sixteen patients received cyclophosphamide and 18 enalapril. IVCYC decreased the median values of SPAP from 41 to 28mmHg (P < 0.001), and enalapril from 35 to 27mmHg (P 0.02). IVCYC reduced more than twice as much SPAP than enalapril (P 0.04). In those patients with SPAP ≥35mmHg, cyclophosphamidedecreased from 43 to 27mmHg (P 0.003), but enalapril was not effective (P 0.14). The NYHA functional class improved only in those with cyclophosphamide (P 0.021). Also IVCYC had a higher frequency of side effects including infections (RR 1.6; 95% CI, 1.001-2.47), and gastrointestinal side effects (RR 14.6; 95% CI,2.15-99.68). We concluded that IVCYC was effective in mild and moderate PH associated with SLE. Further research is needed to evaluate its long-term efficacy.

1 July 2007 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
GOGonzalo Javier Ochoa‐Brust
Gonzalo Javier Ochoa‐Brust
AFAlma Rosa Fernández
Alma Rosa Fernández
GVGerson Jesús Villanueva‐Ruiz
Gerson Jesús Villanueva‐Ruiz
RVRaymundo Velasco
Raymundo Velasco
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
CVClemente Vásquez
Clemente Vásquez
Objective. To evaluate the role a daily intake of 100 mg of ascorbic acid plays in urinary infection prophylaxis during pregnancy. Methods and materials. A single‐blind clinical trial was carried out on pregnant women randomly assigned to the following treatment groups — Group A: oral treatment with ferrous sulphate (200 mg per day), folic acid (5 mg per day) and ascorbic acid (100 mg per day) for 3 months, and Group B: oral treatment with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months. All patients were clinically evaluated, and a urine culture was carried out each month for a period of 3 months. The χ2 and odds ratio were used to compare effects with and without ascorbic acid, and statistical significance was considered at p<0.05. Results. Global frequency of urinary infections was 25%. The presence of urinary infections in Group A (12.7%) was significantly lower than in Group B (29.1%), (p = 0.03, OR = 0.35, CI 95% = 0.13–0.91). Conclusions. Daily intake of 100 mg of ascorbic acid played an important role in the reduction of urinary infections, improving the health level of the gestating women. We recommend additional vitamin C intake for pregnant women in populations which have a high incidence of bacteriuria and urinary infections.

21 October 2011 in Lupus
Verified
Journal Article
Closed access
WRW Rojo-Contreras
W Rojo-Contreras
EOEva Maria Olivas-Flores
Eva Maria Olivas-Flores
JGJi Gamez-Nava
Ji Gamez-Nava
HMH Montoya-Fuentes
H Montoya-Fuentes
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
LLLaura Gonzalez Lopez
Laura Gonzalez Lopez
Cervical human papillomavirus (HPV+) infection is associated with an increased risk of cervical dysplasia. Although the frequency of HPV+ in systemic lupus erythematosus (SLE) has been investigated in some races its prevalence in Hispanic women is still unknown. This cross-sectional study evaluated the prevalence of cervical HPV+ in Mexican women with SLE (n = 34) or rheumatoid arthritis (RA) (n = 43) and in healthy controls (n = 146). These women were interviewed about risk factors for sexually transmitted infections and cervical cytology analysis was performed. HPV+ viral types were identified using PCR: HPV+ was observed in 14.7% of SLE, 27.9% of RA and 30.8% of controls. High-risk HPV types were observed in 11.7% of women with SLE, 27.9% of women with RA, and in 26% of the controls. High-risk viral types 58, 35 and 18 were the most frequently identified in SLE. Two women with SLE had a high-grade squamous intraepithelial lesion and one had cervical cancer. An association was observed between methotrexate utilization, longer duration of therapy with prednisone, and HPV+ in RA or SLE. Thus, there is a high prevalence of cervical HPV infection in Mexican women with SLE or RA, and physicians must be vigilant in preventing the development of cervical dysplasia.

1 March 2002 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
CDCesar E Davila-Gutierrez
Cesar E Davila-Gutierrez
MHMiguel Huerta
Miguel Huerta
CVClemente Vasquez
Clemente Vasquez
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
The present study was carried out to evaluate the effectiveness of nitazoxanide compared with that of quinfamide, mebendazole, or both in the treatment of intestinal protozoa and helminthic infections. A total of 677 stool specimens from children aged 2-12 years living in 3 communities of Colima, México, were analyzed in order to detect the presence of cysts, trophozoites, eggs, or larvae of intestinal protozoa or helminths. A total of 275 infected children were enlisted in a double-blind controlled study and randomly assigned to one of 2 treatment groups: Group A, nitazoxanide (200 mg for 3 days) and Group B, quinfamide (100 mg for 1 day), mebendazole (200 mg for 3 days), or both. A posttreatment fecal examination was conducted on Day 14 from treatment initiation. In Group A (n = 143), the parasitosis eradication rate was superior to that of Group B (n = 132). However, there was no significant difference between the 2 groups (P > 0.05).

1 January 2014 in International Journal of Medical Sciences
Verified
Journal Article
Open access
MRMónica Ríos-Silva
Mónica Ríos-Silva
XTXóchitl Trujillo
Xóchitl Trujillo
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
ESEnrique Sanchez-Pastor
Enrique Sanchez-Pastor
ZUZorayda Urzúa
Zorayda Urzúa
MHMiguel Huerta
Miguel Huerta
Forskolin is a diterpene derived from the plant Coleus forskohlii. Forskolin activates adenylate cyclase, which increases intracellular cAMP levels. The antioxidant and antiinflammatory action of forskolin is due to inhibition of macrophage activation with a subsequent reduction in thromboxane B2 and superoxide levels. These characteristics have made forskolin an effective medication for heart disease, hypertension, diabetes, and asthma. Here, we evaluated the effects of chronic forskolin administration on blood glucose and oxidative stress in 19 male Wistar rats with streptozotocin-induced diabetes compared to 8 healthy male Wistar rats. Rats were treated with forskolin, delivered daily for 8 weeks. Glucose was assessed by measuring fasting blood glucose in diabetic rats and with an oral glucose tolerance test (OGTT) in healthy rats. Oxidative stress was assessed by measuring 8-hydroxydeoxyguanosine (8‑OHdG) in 24-h urine samples. In diabetic rats, without forskolin, fasting blood glucose was significantly higher at the end than at the beginning of the experiment (8 weeks). In both healthy and diabetic rats, forskolin treatment lowered the fasting glucose at the end of the experiment but no effect was found on oral glucose tolerance. The 8-OHdG levels tended to be less elevated in forskolin-treated than in untreated group. Our results showed that chronic administration of forskolin decreased fasting blood glucose levels; however, the reductions of 8-OHdG were not statistically significant.

1 January 2002 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
HMHomero Mireles-Rocha
Homero Mireles-Rocha
IGIgnacio Galindo
Ignacio Galindo
MHMiguel Huerta
Miguel Huerta
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
ATAlejandro Elizalde T
Alejandro Elizalde T
RCRoberto Cortés-Franco
Roberto Cortés-Franco
Ultraviolet radiation absorption is responsible for the production of free radicals in damaged cells...